XML 41 R32.htm IDEA: XBRL DOCUMENT v3.24.3
Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Other Commitments [Line Items]          
Impairment of intangible assets $ 0 $ 0 $ 0 $ 0  
Intangible assets, net 105,515   105,515   $ 65,490
Amortization of intangible assets     9,975 2,728  
Neuren Pharmaceuticals Limited [Member] | License Agreements [Member]          
Other Commitments [Line Items]          
Finite-Lived Intangible Assets, Amortization Expense, Remainder of 2024 2,300   2,300    
Amortization of intangible assets 2,300 $ 1,400 10,000 $ 2,700  
Finite-Lived Intangible Assets, Amortization Expense, Subsequent year 9,400   9,400    
FDA Approval Of DAYBUE [Member] | Neuren Pharmaceuticals Limited [Member] | License Agreements [Member]          
Other Commitments [Line Items]          
Intangible assets, net $ 119,600   $ 119,600